Alexandria Real Estate Equities, Inc. Celebrates 30 Years at the Vanguard and Heart of the $5 Trillion Secularly Growing Life Science Industry

Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science, agtech and advanced technology mega campuses in AAA innovation cluster locations, today celebrates the 30th anniversary of its one-of-a-kind, once-in-a-generation company. Alexandria pioneered the novel Labspace® niche and created the first-ever REIT uniquely focused on the critically important life science industry with its founding on January 5, 1994. Over the past three decades, the company has transformed life science real estate from a specialty niche to a compelling mainstream asset class, and it remains the only publicly traded pure-play life science REIT.

"We are grateful and humbled to celebrate the 30th anniversary of Alexandria's founding — a truly monumental milestone that is a testament to our stellar family team's operational excellence and dedication to our mission-driven business. It is remarkable to reflect on our astounding growth, from our start in basement offices at Jacobs Engineering to our success in creating an irreplaceable life science real estate platform that dominates the asset class we pioneered," said Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc./Alexandria Venture Investments. "Thirty years ago, we saw the remarkable early potential of the life science industry, and today we are honored to be the trusted partner to leaders in this secularly growing industry who rely on our essential Labspace assets to advance and help safeguard their mission-critical work on truly groundbreaking therapies and cures. With over 10,000 diseases known to humankind, nearly 90% of which have no approved treatments, the incredible innovation taking place within our Labspace facilities is and will remain a national imperative. We are immensely proud, as Jim Collins has said, to have 'achieved the three outputs that define a great company: Superior Results, Distinctive Impact and Lasting Endurance,' and we will continue to build upon these outputs to transition the company into the next generation."

Alexandria's superior results have been accelerated by its first-mover advantage in the top life science clusters, high-quality Labspace assets aggregated in desirable mega campuses, longstanding tenant relationships and highly experienced team with deep life science expertise. The company's execution of its multifaceted platform of internal and external growth continues to generate outstanding long-term total stockholder return (TSR). From its IPO in May 1997 through December 31, 2023, Alexandria has generated a TSR of 1,512%, significantly outperforming major indices over the same period, including the FTSE Nareit Equity Health Care Index's TSR of 980% and the MSCI US REIT Index's TSR of 792% (assuming reinvestment of dividends). Additionally, Alexandria's growth and sustained performance are supported by its fortress balance sheet with no debt maturities prior to 2025, 99.0% of debt at fixed rates, credit ratings ranking among the top 10% of all publicly traded U.S. REITs and significant liquidity of $5.9 billion as of September 30, 2023.

For 30 years, Alexandria has been making a distinctive impact as the leader in delivering the complex laboratory infrastructure and fostering the holistic ecosystems needed to enable innovation to advance life-changing treatments and cures. Half of all FDA-approved therapies since 2013 have come from Alexandria's tenants, demonstrating the company's meaningful impact on human health. Alexandria is committed to partnering on endeavors that aim to better manage disease and reduce its economic burden on society, including by addressing two of the country's most prevalent and complex public health issues — addiction and mental health — through its social responsibility pillars. According to CDC data, more than 110,000 people died from drug overdoses in the United States in 2022, and suicide deaths reached an all-time high of nearly 49,500. In the face of the opioid epidemic in 2017, Alexandria partnered with Verily to pioneer OneFifteen, a personalized, data-driven care model for treating addiction, in Dayton, Ohio — a city with one of the highest per capita overdose death rates in the nation that year. Alexandria designed and developed a state-of-the-art campus with a full continuum of care, including medication-assisted treatment, residential housing, peer support and job placement. OneFifteen has treated over 7,500 patients since opening four years ago. Alexandria has also been partnering with the Navy SEAL Foundation since 2010, enabling the foundation to address the increasing need for specialized physical and mental health programs for Naval Special Warfare personnel and their families. Alexandria is supporting the foundation's new, cutting-edge Warrior Fitness Program West Coast facility in San Diego. The holistic facility provides Navy SEAL warriors and veterans with evidence-based support, advanced technology resources and expert personnel to help them physically and mentally recover and rebuild from injuries and trauma, as well as transition to civilian life.

Alexandria was founded on the belief that life science companies are most successful when positioned in the epicenter of top innovation ecosystems proximate to world-renowned academic medical institutions, deep specialized talent and ample risk capital. This belief shaped its cluster model, which it has applied to the life science industry in a disciplined manner to drive the company's lasting endurance. Since 1994, Alexandria has strategically and methodically created the highest-quality life science asset base primarily concentrated in high-barrier-to-entry markets and built the leading life science infrastructure platform. As of September 30, 2023, Alexandria has the strategic optionality to almost double the size of its asset base from 41.5 million RSF of operating properties to 75.1 million SF with assets on balance sheet to continue to meet the unique needs of the vital and secularly growing life science industry.

Read Full Article Here

Previous
Previous

Amgen to Build Generative AI Models for Novel Human Data Insights and Drug Discovery

Next
Next

UCLA will transform dead Westside mall into major science innovation center